Seagen is dedicated to our goal of ensuring that all patients are represented in our clinical trials. It is important to Seagen that the therapies we make improve the lives of all people with cancer, including those who have been historically underrepresented due to their sex, race, ethnicity, or age. — Seagen Commitment to Diversity & Inclusion
In the ECHELON-3 study, about 400 participants with DLBCL will be randomized into two groups. There will be about 200 subjects in each group.
The group you are in will be chosen randomly, like tossing a coin. Neither you nor the study team will know which group you are in until the end of the study.
Please select the closest site to you and Seagen will work with you to access travel and lodging support.
Sites are located in the cities/states identified with the red pin:
Study participation may last up to 5 years, and the study is divided into the following periods: